Business Description
ImmuPharma PLC
NAICS : 325412
One Bartholomew Close, London, GBR, EC1A 7BL
Compare
Compare
Traded in other countries / regions
ALIMM.Belgium
•
25I.Germany
•
IMM.UK
•
IMMPF.USA
Description
ImmuPharma PLC is a drug discovery and development company. Its pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity & Inflammation, Anti-Infectives, Metabolism, and Cancer. Its lead drug candidate is Lupuzor, which is a treatment for lupus and life-threatening autoimmune disease.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1599 | |||||
| Equity-to-Asset | 0.74 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.33 | |||||
| Beneish M-Score | -5.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | 14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 14.1 | |||||
| 3-Year FCF Growth Rate | 18.4 | |||||
| 3-Year Book Growth Rate | -35.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.42 | |||||
| 9-Day RSI | 59.27 | |||||
| 14-Day RSI | 54.55 | |||||
| 6-1 Month Momentum % | -13.81 | |||||
| 12-1 Month Momentum % | -20.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.11 | |||||
| Quick Ratio | 2.11 | |||||
| Cash Ratio | 1.01 | |||||
| Days Sales Outstanding | 854.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4335.29 | |||||
| Net Margin % | -6868.91 | |||||
| ROE % | -126.53 | |||||
| ROA % | -102.19 | |||||
| ROIC % | -134.64 | |||||
| ROC (Joel Greenblatt) % | -1178.08 | |||||
| ROCE % | -136.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.95 | |||||
| Price-to-Tangible-Book | 5.93 | |||||
| EV-to-EBIT | -2.02 | |||||
| EV-to-EBITDA | -2.05 | |||||
| EV-to-Revenue | 149.71 | |||||
| EV-to-FCF | -3.65 | |||||
| Price-to-Net-Current-Asset-Value | 5.93 | |||||
| Earnings Yield (Greenblatt) % | -49.5 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.119 | ||
| EPS (TTM) (£) | -0.033 | ||
| Beta | 1.54 | ||
| Volatility % | 50.72 | ||
| 14-Day RSI | 54.55 | ||
| 14-Day ATR (£) | 0.00511 | ||
| 20-Day SMA (£) | 0.057845 | ||
| 12-1 Month Momentum % | -20.61 | ||
| 52-Week Range (£) | 0.048 - 0.095 | ||
| Shares Outstanding (Mil) | 327.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuPharma PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||